Therapy News and Research

RSS

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

No effort for ensuring continuity of supports and services as ASD children age into adulthood: Study

What happens to young adults with autism spectrum disorders (ASDs) once they graduate high school and are no longer entitled to services?

9 Feb 2011

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial.

9 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

DiaTech Oncology announced today they have engaged in a pilot with Walter Reed Army Medical Center to determine the best Chemotherapy for Cancer patients. Medical and GYN Oncologists and from Walter Reed have been working with DiaTech Oncology (Nashville, TN) using the MiCK assay for apoptosis in order to give physicians a tool that can predict the best chemotherapy pathway in treating cancer patients.

9 Feb 2011

International AIDS Society urges donors and governments to continue funding

Following the publication of several media reports which seriously distort the extent of fraud discovered in grants financed by the Global Fund to Fight AIDS, TB and Malaria, the International AIDS Society (IAS) urges all donors and governments to continue their funding.

9 Feb 2011

Research findings highlight potential for noninvasive MSC delivery to treat Parkinson disease

Successful intranasal delivery of stem cells to the brains of rats with Parkinson disease yielded significant improvement in motor function and reversed the dopamine deficiency characteristic of the disease.

9 Feb 2011

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.

9 Feb 2011

Karo Bio fourth quarter net loss increases to MSEK 50.1

The January - December period and fourth quarter 2010 in brief

9 Feb 2011

Study finds breast cancer patients do not benefit from axillary lymph node dissection

Among patients with early-stage breast cancer that had spread to a nearby lymph node and who received treatment that included lumpectomy and radiation therapy, women who just had the sentinel lymph node removed did not have worse survival than women who had more extensive axillary lymph node dissection, according to a study in the February 9 issue of JAMA.

9 Feb 2011

New You Magazine about anti-aging management to re-launch in March

New You, the premier American consumer magazine about cosmetic surgery, will re-launch in March as the voice of the anti-aging industry in a strategic partnership with the American Academy of Anti-Aging Medicine.

9 Feb 2011

Study finds dutasteride not cost-effective in prevention of prostate cancer in men at elevated risk

The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

9 Feb 2011

Revo pacemaker receives FDA approval for use during certain MRI exams

The U.S. Food and Drug Administration today approved the first heart pacemaker designed to be used safely during certain magnetic resonance imaging (MRI) exams.

9 Feb 2011

NivaSonix receives USPTO notice of allowance for 'External Ultrasound Lipoplasty' patent

NivaSonix, LLC announced today the allowance by the U. S. Patent and Trademark Office (USPTO) of its core patent "External Ultrasound Lipoplasty". Nine additional U.S. and international patents are pending with additional patent filings in progress. The patent describes a technology that allows a new generation of non-invasive ultrasound therapy for both fat and wrinkle reduction targeted for patients worldwide.

9 Feb 2011

DE-MRI holds promise for predicting risks of strokes

Researchers at the University of Utah's Comprehensive Arrhythmia and Research Management Center have found that delayed-enhancement magnetic resonance imaging holds promise for predicting the risks of strokes, the third leading cause of death in the U.S.

9 Feb 2011

Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

Gentium S.p.A. today announced that ongoing preclinical and clinical studies on Defibrotide have been completed and confirmed its plan to file for regulatory approval of Defibrotide with the US Food and Drug Administration and the European Medicines Agency by the end of the second quarter of 2011.

9 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

Kindred Healthcare signs definitive merger agreement to acquire RehabCare

Kindred Healthcare, and RehabCare Group, today jointly announced the signing of a definitive merger agreement under which Kindred will acquire RehabCare.

8 Feb 2011

New insight into AMD related blindness

more than 50 million worldwideA new study in the journal Nature has reported the pathology of blindness caused by age-related macular degeneration or AMD. This condition affects more than 50 million worldwide and is incurable. The researchers report that when an enzyme known as DICER1 stops functioning AMD starts to develop.

8 Feb 2011

Service disengagement rates are high in youths with autism spectrum disorder after high school

Use of medical, mental health and case management services for young adults with an autism spectrum disorder appears to decline after high school, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

8 Feb 2011

Therapy News and Research

Everolimus phase III study shows improved progression-free survival in patients with pNET

No effort for ensuring continuity of supports and services as ASD children age into adulthood: Study

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

International AIDS Society urges donors and governments to continue funding

Research findings highlight potential for noninvasive MSC delivery to treat Parkinson disease

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Karo Bio fourth quarter net loss increases to MSEK 50.1

Study finds breast cancer patients do not benefit from axillary lymph node dissection

New You Magazine about anti-aging management to re-launch in March

Study finds dutasteride not cost-effective in prevention of prostate cancer in men at elevated risk

Revo pacemaker receives FDA approval for use during certain MRI exams

NivaSonix receives USPTO notice of allowance for 'External Ultrasound Lipoplasty' patent

DE-MRI holds promise for predicting risks of strokes

Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Kindred Healthcare signs definitive merger agreement to acquire RehabCare

New insight into AMD related blindness

Service disengagement rates are high in youths with autism spectrum disorder after high school

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News